{"id":510395,"date":"2021-07-07T09:39:04","date_gmt":"2021-07-07T13:39:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/"},"modified":"2021-07-07T09:39:04","modified_gmt":"2021-07-07T13:39:04","slug":"biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/","title":{"rendered":"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology"},"content":{"rendered":"<h2>\nThe Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>Westport, CT, July  07, 2021  (GLOBE NEWSWIRE) &#8212; BioSig Technologies, Inc. (Nasdaq: BSGM) (&#8220;BioSig&#8221; or the &#8220;Company&#8221;), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its technology in a leading New York City hospital.<\/p>\n<p>The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites. <\/p>\n<p>The Northeast is one of the three strategic areas that the Company is focused on in the targeted commercial launch phase. BioSig\u2019s PURE EP(tm) technology was installed at New York Presbyterian \/ Weill Cornell Medical Center in New York, NY, one of the nation\u2019s most comprehensive, integrated healthcare systems and New York\u2019s top-ranked hospital for 20 years<sup>1<\/sup>. Weill Cornell Medical Center which has commenced conducting patient cases with the PURE EP(tm) System in June 2021, offers one of the most extensive electrophysiology programs in the country. <\/p>\n<p>\u201cWe are pleased to commence patient cases at one of the best-ranked centers for cardiology in our country and a leading institution in the New York City area. Our clinical strategy focuses on engaging medical centers of excellence that are recognized for their commitment to patient care and their support of clinical innovation and research, and we look forward to advancing our efforts with the Weill Cornell physician team,\u201d commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. <\/p>\n<p>The PURE EP(tm) System has been awarded FDA 510(k) clearance. The Company commenced a targeted commercial launch in 2020 and completed commercial sales to St. David\u2019s HealthCare of Austin, Texas, an HCA Healthcare-owned hospital, and Mayo Foundation for Medical Education and Research that acquired multiple PURE EP(tm) units for clinical use across their Minnesota, Florida and Arizona campuses.<\/p>\n<p>One in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 2050<sup>2<\/sup>.\u00a0According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually<sup>3<\/sup>.<\/p>\n<p>\n        <strong>About BioSig Technologies <\/strong><br \/>\n        <br \/>BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bFKRuOxW25-umlgZwxETaBlpQIRmKoOn6-D0JRkDUC3xjvoJggNMebc2k0Fyg9E2I036A9t1RWOVfRNROnmcig==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.biosig.com<\/u><\/a>).<\/p>\n<p>The Company\u2019s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.<\/p>\n<p>\n        <strong>Forward-looking Statements <\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at http:\/\/www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.<\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup> New York-Presbyterian website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZyDD2EQEjTr2No8i3KtmmuMvgqkMHLBiv7AY8G-e9N6YzYRsX8N8WI7x40VEoY2cEn2iIM0nd2Qyo8GUEE4gYQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.nyp.org<\/u><\/a><\/p>\n<p>\n        <sup>2<\/sup> Top 10 Things You should Know About Heart Rhythm; Scripps Health.<\/p>\n<p>\n        <sup>3<\/sup> Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4<\/p>\n<p>\n        \n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/db71e039-16b9-4b2c-9735-e73bdc7644f4\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Andrew Ballou\r\nBioSig Technologies, Inc. \r\nVice President, Investor Relations \r\n54 Wilton Road, 2nd floor\r\nWestport, CT 06880\r\naballou@biosigtech.com\r\n203-409-5444, x133\r\n\r\n<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) &#8212; BioSig Technologies, Inc. (Nasdaq: BSGM) (&#8220;BioSig&#8221; or the &#8220;Company&#8221;), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its technology in a leading New York City hospital. The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites. The Northeast is one of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510395","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) &#8212; BioSig Technologies, Inc. (Nasdaq: BSGM) (&#8220;BioSig&#8221; or the &#8220;Company&#8221;), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its technology in a leading New York City hospital. The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites. The Northeast is one of the &hellip; Continue reading &quot;BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T13:39:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology\",\"datePublished\":\"2021-07-07T13:39:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/\"},\"wordCount\":813,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/\",\"name\":\"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=\",\"datePublished\":\"2021-07-07T13:39:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/","og_locale":"en_US","og_type":"article","og_title":"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology - Market Newsdesk","og_description":"The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) &#8212; BioSig Technologies, Inc. (Nasdaq: BSGM) (&#8220;BioSig&#8221; or the &#8220;Company&#8221;), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its technology in a leading New York City hospital. The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites. The Northeast is one of the &hellip; Continue reading \"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T13:39:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology","datePublished":"2021-07-07T13:39:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/"},"wordCount":813,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/","name":"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=","datePublished":"2021-07-07T13:39:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjA0MSM0Mjg1MDI1IzIwMTgwNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biosig-enters-the-new-york-market-with-its-signal-processing-technology-for-electrophysiology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510395"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510395\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}